As I will explain below, this is to successfully target the RBM39 protein, which is functionally similar to that of undruggable target CDK12. Having said that, the company initiated dosing in a ...

Study: CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13. Image Credit: Kateryna Kon/Shutterstock.com In a recent study ...

Now, researchers have revealed a new role for the CDK12 protein. Metastatic ovarian, prostate and breast cancers are notoriously difficult to treat and often deadly. Now, Salk Institute ...

In prostate cancer, inactivating CDK12 mutations lead to gene fusion–induced neoantigens and possibly sensitivity to immunotherapy. We aimed to clinically, pathologically, and molecularly characterize ...

CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13. Cell Reports Medicine , 2024; 101758 DOI: 10.1016/j.xcrm.2024.101758 ...

Researchers in the U.S. and U.K. have identified a new subtype of prostate cancer that is characterized by loss of both copies of the CDK12 gene, and which an early clinical study showed can ...

Scientists at the University of Nottingham have taken a step closer towards developing a treatment for the long-term genetic disorder, myotonic dystrophy. In a paper published today in the journal ...

The advent of immune checkpoint blockade therapies that use programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors for the treatment of multiple cancer types represents a major ...

In a recent study published in Cell Reports Medicine, researchers investigated whether loss of the cyclin-dependent kinase 12 (CDK12) gene drives prostate cancer (PCa) development. Cyclin ...